Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER_GOV × Mid-low Rectal Cancer × tislelizumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Stomach Neoplasms 4 Esophageal Neoplasms 3 Carcinoma, Hepatocellular 3 Colorectal Neoplasms 2 Carcinoma, Non-Small-Cell Lung 2 SCLC, Extensive Stage 1 Nasopharyngeal Carcinoma 1 Mid-low Rectal Cancer 1 Melanoma 1 Locally Advanced Rectal Cancer 1 Laryngeal Neoplasms 1 Immunotherapy 1 Hypopharyngeal Neoplasms 1 Colonic Neoplasms 1 Advanced Non-small-cell Lung Cancer 1

Interventions

tislelizumab 1 Oxaliplatin 1 Capecitabine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06333769 2025-08-15

Modified SCRT Followed by Tislelizumab Plus CAPOX for Locally Advanced Rectal Cancer

Fujian Cancer Hospital

Phase 2 Completed

Gastrointestinal

Mid-low Rectal Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡